Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.
about
Hypoxia-inducible factors and the response to hypoxic stressHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionOn-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsThe role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapyHypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1AlphaHypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaBVHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2.The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma.VHL, the story of a tumour suppressor gene.The multifaceted von Hippel-Lindau tumour suppressor protein.The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.Mitochondrial dysfunction impairs tumor suppressor p53 expression/function.Reciprocal influence of the p53 and the hypoxic pathwaysLow expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway.Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic successRING finger protein 31 promotes p53 degradation in breast cancer cells.Noncytotoxic differentiation treatment of renal cell cancer.The VHL/HIF axis in clear cell renal carcinoma.Loss of VHL promotes progerin expression, leading to impaired p14/ARF function and suppression of p53 activity.Combined mutation of Vhl and Trp53 causes renal cysts and tumours in miceHIF isoforms in the skin differentially regulate systemic arterial pressure.Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.The growing complexity of HIF-1α's role in tumorigenesis: DNA repair and beyond.The impact of hypoxia on cell death pathways.Apoptotic cell death under hypoxia.JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin.Implications of Oxygen Homeostasis for Tumor Biology and Treatment.Hypoxia: A Double-Edged Sword in Cancer Therapy.Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathwaysEpigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.A new connection between VHL and cancer threads through progerin.The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells.K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair.Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?Aqueous Extracts of Toona sinensis Leaves Inhibit Renal Carcinoma Cell Growth and Migration Through JAK2/stat3, Akt, MEK/ERK, and mTOR/HIF-2α Pathways.
P2860
Q24629323-E7B93C2C-26EF-40C3-861E-D79F18C66775Q27025886-358F1718-E2CC-435E-9F87-7DB489A0A6EEQ27727998-D1991681-15B4-4C7D-BE04-27C8AE90EE20Q28067724-046FD04A-9986-4D4A-B5EE-40B701A211C7Q28533909-DE910D76-49B7-4654-A7A7-34BD162AA787Q33656653-98536AB7-3E42-4944-B7F5-FC0201E96FFCQ33826897-C229B816-96EC-4A4E-B696-652140A77CAFQ34351080-4D14F2CA-5768-40E2-9263-3B34A52DC027Q34365715-4D701D92-A15A-4BEC-8544-40198CDBAE5CQ34455226-8FC06C06-F271-4ED0-9956-61B3DE15E404Q34660062-C727B020-1EB9-4C0C-BF55-8F373DDAC732Q35009536-7DC50644-9814-42CE-BE6A-9FB187ED0C71Q35063355-D4C1A345-7FB1-4FD8-AB1B-355AAE4E9F71Q35065006-C1A915C8-012C-4BD9-A065-E60FCB42DE3CQ35728921-E0B2A7E3-C556-4483-A1BA-813F1B31BD00Q35906539-ED8A30D1-7074-4A54-AF65-16BF461A0A35Q36804413-E7A39AF0-9522-40B9-ACAC-6DD20372A8CEQ36866357-FAA5571F-C594-437C-AC81-677339A6F768Q36872295-53526F42-D20B-438D-AE71-8C1BD0A4D3C3Q37126195-E491B320-C2C2-4329-B12C-D2FF2A975670Q37188593-AF428B41-DAB4-447D-BF3C-FBF86B8F422DQ37255955-1F7C5BCF-17D1-43D3-8AD7-DFA165A842D2Q37499251-2F9E175D-D5FD-4226-B5F5-07E552FDF019Q37882456-D0870187-75F8-4339-9EF2-0E4B476B9732Q37884379-97508C77-6F74-4AF8-A2DC-05FA3A50F147Q38003390-0602A2AB-BA80-4355-996D-BE0F3C320D0EQ38060522-C5623B40-8963-4A41-A834-BD2A96CDA2CEQ38091503-61A61B94-A54C-4378-ADFA-608A31269039Q38208805-DEA3DA3B-DBBB-4DED-BFCF-E32934094873Q38700491-48601697-3E3D-4DD3-AC06-42F5E2686549Q38876568-35096BCC-328E-456E-9ABB-EC4AC8CEDEBDQ39002822-0A814787-F8A1-4396-8E71-AAB27BA0002BQ39077231-B363056A-C807-4168-9F06-AB6129696105Q39490284-1BEB6D47-03C6-417E-9298-836C6B19E29DQ41827079-83C41598-5318-40DC-B7FB-D297F84BC6CAQ41908755-1E709F4E-51C0-4E96-A8B8-4CD3CA7F82D3Q45363184-DDF03EAA-32B1-4365-88E9-AEEBE2B90FC2Q47979679-77B45205-3B5F-4EC9-82D2-D07F18C0C042Q52778165-39153625-934B-488E-87E1-AAEBEB53C6EDQ53114366-08FBD7C7-6719-4C9C-AF9D-AAA7734D3243
P2860
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.
@en
Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.
@nl
type
label
Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.
@en
Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.
@nl
prefLabel
Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.
@en
Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.
@nl
P2093
P2860
P1433
P1476
Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.
@en
P2093
Andrew J Evans
Andrew M Roberts
David A Foster
Ian R Watson
Meredith S Irwin
Michael Ohh
P2860
P304
P356
10.1158/0008-5472.CAN-09-1770
P407
P577
2009-11-17T00:00:00Z